Skip to content

Exploring the immunological competence of the meninges and bone marrow in neurological diseases

Exploring the immunological competence of the meninges and bone marrow in neurological diseases - ENDURE

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON56851
Enrollment
100
Registered
2024-05-15
Start date
2025-01-03
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoom glioom

Interventions

None listed

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • 18 years of age, or older • Subjected to a neurosurgical intracranial operation

Exclusion criteria

Exclusion criteria: - Participants of whom the required tissues cannot be accessed due to the  operative route and strategy or of whom the tissue cannot be safely collected,  including individuals of whom no autologous duraplasty can be harvested. - Individuals with inherent bleeding disorders. - Individuals with an inherent or acquired immunodeficiency and/or medications  that suppress wound healing (except dexamethasone).

Design outcomes

Primary

MeasureTime frame
Differences in (immune) cell composition (type of immune cells and abundance) and behaviour (as measured by gene and protein expression profiles and cell localization) of the meninges and skull bone marrow between patients with high-grade glioma and non-glioma controls.

Secondary

MeasureTime frame
Tissues will be made part of a biobank.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)